AGL 38.41 Decreased By ▼ -0.07 (-0.18%)
AIRLINK 198.00 Decreased By ▼ -5.02 (-2.47%)
BOP 9.94 Decreased By ▼ -0.23 (-2.26%)
CNERGY 6.40 Decreased By ▼ -0.14 (-2.14%)
DCL 9.37 Decreased By ▼ -0.21 (-2.19%)
DFML 39.45 Decreased By ▼ -0.57 (-1.42%)
DGKC 97.77 Decreased By ▼ -0.31 (-0.32%)
FCCL 35.30 Increased By ▲ 0.34 (0.97%)
FFBL 86.83 Increased By ▲ 0.40 (0.46%)
FFL 13.62 Decreased By ▼ -0.28 (-2.01%)
HUBC 129.50 Decreased By ▼ -2.07 (-1.57%)
HUMNL 13.99 Decreased By ▼ -0.03 (-0.21%)
KEL 5.25 Decreased By ▼ -0.36 (-6.42%)
KOSM 7.31 Increased By ▲ 0.04 (0.55%)
MLCF 45.43 Decreased By ▼ -0.16 (-0.35%)
NBP 61.60 Decreased By ▼ -4.78 (-7.2%)
OGDC 214.69 Decreased By ▼ -6.07 (-2.75%)
PAEL 39.27 Increased By ▲ 0.79 (2.05%)
PIBTL 8.56 Decreased By ▼ -0.35 (-3.93%)
PPL 190.40 Decreased By ▼ -7.48 (-3.78%)
PRL 40.50 Increased By ▲ 1.47 (3.77%)
PTC 25.53 Increased By ▲ 0.06 (0.24%)
SEARL 106.00 Increased By ▲ 2.95 (2.86%)
TELE 8.70 Decreased By ▼ -0.32 (-3.55%)
TOMCL 36.20 Decreased By ▼ -0.21 (-0.58%)
TPLP 14.04 Increased By ▲ 0.29 (2.11%)
TREET 24.80 Decreased By ▼ -0.32 (-1.27%)
TRG 56.20 Decreased By ▼ -1.84 (-3.17%)
UNITY 33.40 Decreased By ▼ -0.27 (-0.8%)
WTL 1.63 Decreased By ▼ -0.08 (-4.68%)
BR100 11,811 Decreased By -78.7 (-0.66%)
BR30 36,716 Decreased By -640.5 (-1.71%)
KSE100 109,676 Decreased By -1394.1 (-1.26%)
KSE30 34,484 Decreased By -424.7 (-1.22%)
World

WHO says awaits EMA, FDA reviews of J&J COVID-19 vaccine, monitoring global data

  • U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson's COVID-19 vaccine after six women under 50 given the shot developed rare blood clots.
Published April 13, 2021 Updated April 14, 2021

GENEVA: The World Health Organization, asked about reports of rare blood clots after vaccination with the Johnson & Johnson COVID-19 shot, told Reuters on Tuesday that it awaited reviews by the U.S. and European regulators and was monitoring global data.

"We're watching closely, waiting for EMA (European Medicines Agency) and FDA (U.S. Food and Drug Administration) reviews and monitoring the global database of adverse event reports to see if there have been cases anywhere else," the WHO said in an email reply. "It will take a little time to review the data."

U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson's COVID-19 vaccine after six women under 50 given the shot developed rare blood clots.

Following the news, J&J said it was delaying the rollout of the vaccine to Europe, a week after regulators there said they were reviewing rare blood clots in four recipients of the shot in the United States.

Comments

Comments are closed.